OncoPharm

Latest Episodes:

PGYNone: Dandelion Effect Nov 20, 2025

Show notes

Our 3rd and final installment in this Oncology Pharmacy Training Pathways mini-series discusses the PGYNone route. I am joined by Vineetha Thomas and Sheila Pierre to discuss their experiences in becoming oncology pharmacists, forgoing residency training, positions they held earlier in their career, and ultimately becoming thriving oncology pharmacists. This mini-series is supported by the ELO Collaborative, a fantastic training opportunity for those seeking get more oncology training outside traditional pathways. Use this link to explore: https://elojbossaer--kelleycpharmd.thrivecart.com/elo-collaborative-1-year/651082f1e4e3c/ There is no universal pathway to become an oncology pharmacist, and the discussions in this mini-series reflect the views & experiences of those involved.

PGY1 Pathway: Road Trip! Nov 13, 2025

Show notes

Our 2nd installment in this Oncology Pharmacy Training Pathways mini-series discusses the PGY1 pharmacy residency route, without a PGY2 oncology residency. I am joined by Kayla Fry and Amber Burgess to discuss their experience to becoming oncology pharmacists. There are some similarities and differences in their paths to their current roles (and one It's-A-Small-World shared connection too!) This mini-series is supported by the ELO Collaborative, a fantastic training opportunity for those seeking get more oncology training outside traditional pathways. Use this link to explore: https://elojbossaer--kelleycpharmd.thrivecart.com/elo-collaborative-1-year/651082f1e4e3c/ The last episode in this mini-series will cover the PGY-NONE pathway of becoming an oncology pharmacist. There is no universal pathway to become an oncology pharmacist, and the discussions in this mini-series reflect the views & experiences of those involved.

PGY2 Pathway: A Planned City Nov 06, 2025

Show notes

Our 1st installment in this Oncology Pharmacy Training Pathways mini-series discusses the PGY2 oncology pharmacy residency rout. I am joined by Brooke Adams and Sarah Wheeler to discuss our experience and PGY2 training. We discuss the pros/cons of pursuing a PGY2 oncology residency with the understanding that residency training (or additional residency) training isn't for everyone. This mini-series is supported by the ELO Collaborative, a fantastic training opportunity for those seeking get more oncology training outside traditional pathways. Use this link to explore: https://elojbossaer--kelleycpharmd.thrivecart.com/elo-collaborative-1-year/651082f1e4e3c/ The next two episodes in the mini-series will cover the PGY1 pathway and the PGY-NONE pathway of becoming an oncology pharmacist. There is no universal pathway to become an oncology pharmacist, and the discussions in this mini-series reflect the views & experiences of those involved.

Tale from the Crypt: Belantamab Mafodotin Oct 30, 2025

Show notes

[Moving Trailer Voice] This Halloween: They always come back.... The latest revival is belantamab mafodotin, FDA approved...again. After being vanquished in DREAMM3, it returned in DREAMM7 and even Daratumumab (in combination with Vd) couldn't overcome this blindingly effective drug (in combination with Vd). This pod reviews belantamab mafodotin's checkered past and wonders what the sequels may have in store for us.

ESMO 2025 Oct 23, 2025

Show notes

This week's episode recaps some highlights from ESMO 2025: 1. Destiny-Breast05: T-DXd > T-DM1 in persistent HER2+ disease after neoadjuvant chemo + surgery 2. Keynote-905: Neoadjuvant Enfortumab Vedotin + pembro in cisplatin-ineligible bladder cancer 3. POTOMAC: Durvalumab + BCG in non-muscle invasive bladder cancer 4. IMvigor011: ctDNA-guided adjuvant atezolizumab in bladder cancer 5. Dynamic-III: ctDNA guide de-escalation or escalation of chemotherapy in stage III colon cancer 6. HARMONi-6: an excuse to talk about ivonescimab, a bispecific antibody unlike any other currently FDA approved

IL-2 Oct 16, 2025

Show notes

IL-2, one of the founding fathers of our current immunotherapy landscape, is discussed.

Maintenance Therapy in Small Cell Lung Cancer Oct 09, 2025

Show notes

Maintenance therapy with ICIs (atezolizumab or durvalumab) is already established in extensive stage small-cell lung cancer, but lurbinectedin enters the chat with a recent FDA approval. Next up - tarlatamab? IMforte (maintenance lurbinectedin + atezolizumab): https://doi.org/10.1016/S0140-6736(25)01011-6 DeLLphi-303 (phase 1b maintenance tarlatamab + ICI): https://doi.org/10.1016/S1470-2045(25)00480-2

PARAMOUNT - Maintenance Pemetrexed Oct 03, 2025

Show notes

Our Landmarks of OncoPharm series returns to discuss PARAMOUNT, a landmark study that helped solidify the role of maintenance pemetrexed in NSCLC.

SC Pembro, Biotin, 5-yr POLARIX data Sep 25, 2025

Show notes

The long awaited subcutaneous formulation of pembrolizumab is not FDA-approved. We discuss its administration and toxicity & PK differences vs. IV use. Biotin supplementation can interfere with lots of labs cancer patients get routinely - Who knew? (Ahem, not me.) Link: https://doi.org/10.1200/OP-25-00693 POLARIX 5-year Data: https://doi.org/10.1200/JCO-25-00925

ALASCCA Sep 21, 2025

Show notes

We discuss the ALASCCA study (Adjuvant Low-doseASpirin in Colorectal CAncer

Our TOPPODCAST Picks

Follow Us

Stay Connected

Related Podcasts

Links

Stay Connected